---
figid: PMC2442829__nihms51320f2
figlink: /pmc/articles/PMC2442829/figure/F2/
number: F2
caption: Several approaches can be employed when combining pathway inhibitors with
  other targeted therapies. Inhibition of proximal pathway components, such as receptor
  tyrosine kinases (RTKs) and oncogenes, combined with distal inhibition of Akt or
  mTOR may be an effective approach to circumvent feedback activation that could occur
  with distal inhibition alone (left panel). Alternatively, dual inhibition of parallel
  signaling pathways prevents compensatory activation of redundant pro-survival pathways
  (middle panel). Finally, pathway inhibition can be combined with several other types
  of targeted therapies, including inhibition of histone deacetylase complexes (HDAC),
  the proteasome and cyclooxygenase-2 (COX-2) (right panel).
pmcid: PMC2442829
papertitle: 'Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical
  considerations.'
reftext: Jaclyn LoPiccolo, et al. Drug Resist Updat. ;11(1-2):32-50.
pmc_ranked_result_index: '38099'
pathway_score: 0.8358094
filename: nihms51320f2.jpg
figtitle: 'Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical
  considerations'
year: ''
organisms: Homo sapiens
ndex: 7b78c8dc-df12-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2442829__nihms51320f2.html
  '@type': Dataset
  description: Several approaches can be employed when combining pathway inhibitors
    with other targeted therapies. Inhibition of proximal pathway components, such
    as receptor tyrosine kinases (RTKs) and oncogenes, combined with distal inhibition
    of Akt or mTOR may be an effective approach to circumvent feedback activation
    that could occur with distal inhibition alone (left panel). Alternatively, dual
    inhibition of parallel signaling pathways prevents compensatory activation of
    redundant pro-survival pathways (middle panel). Finally, pathway inhibition can
    be combined with several other types of targeted therapies, including inhibition
    of histone deacetylase complexes (HDAC), the proteasome and cyclooxygenase-2 (COX-2)
    (right panel).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - EGFR
  - NRAS
  - MAPK3
  - AKT1
  - PIK3CB
  - AKT2
  - MAP2K2
  - MDM2
  - MAP2K1
  - BIRC3
  - AKT3
  - PIK3R4
  - PIK3CA
  - MET
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - HDAC1
  - MTOR
  - PIK3R5
  - PIK3R6
  - ARAF
  - KRAS
  - ERBB2
  - HRAS
  - HDAC2
  - RAF1
  - HDAC3
  - TP53
  - BRAF
  - HDAC8
  - LY294002
  - perifosine
  - sulindac
  - rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: mdm2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: API-2
  symbol: API2
  source: hgnc_prev_symbol
  hgnc_symbol: BIRC3
  entrez: '330'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: C-met
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: her2/neu
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: her2/neu
  symbol: NEU
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
chemicals:
- word: LY294002
  source: MESH
  identifier: C085911
- word: perifosine
  source: MESH
  identifier: C105905
- word: sulindac
  source: MESH
  identifier: D013467
- word: rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC2442829__F2
redirect_from: /figures/PMC2442829__F2
figtype: Figure
---
